STAT+: FDA appears open to Moderna’s flu vaccine ahead of adcomm

STAT PlusNewsletterThe Readout FDA appears open to Moderna’s flu vaccine ahead of adcomm UniQure will submit Huntington’s therapy for approval, Eli Lilly buys 4E Therapeutics, and more biotech news Manage alerts for this article Email this article Share this article By Elaine Chen and Helen BranswellJune 17, 2026 Elaine Chen[email protected]Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.Helen BranswellHelen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Follow her on Mastodon and Bluesky. You can reach Helen on Signal at hbranswell.01. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Today, one venture capitalist weighs in on the China biotech debate. Let me know if you agree with her or not.Advertisement UniQure will submit Huntington’s therapy for approval The FDA has reversed its opposition to a closely watched experimental treatment for Huntington’s disease, clearing a path for its maker, the biotech company UniQure, to file for U.S. approval, the company said morning. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Drug prices, research Submit a correction requestReprints Elaine Chen National Biotech Reporter Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Helen Branswell Infectious Diseases Correspondent Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Follow her on Mastodon and Bluesky. You can reach Helen on Signal at hbranswell.01. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Biotech June 17, 2026 STAT Plus: Following dispute with FDA, UniQure is cleared to submit Huntington’s treatment for approval Biotech June 17, 2026 STAT Plus: A prominent VC explains why she’s against U.S. restrictions on investment in China’s drug industry Advertisement The Readout June 16, 2026 STAT Plus: ARCH-launched Neumora stops depression program Biotech June 16, 2026 STAT Plus: Verge Labs’ new AI model solves patient stratification problems for neurology clinical trials Politics June 15, 2026 STAT Plus: Trump’s obesity drug plan creates a temporary Medicare program that may be hard to end Subscriber Picks